Vinita Takiar1, Adam S Garden2, Dominic Ma2, William H Morrison2, Mark Edson2, Mark E Zafereo3, Gary B Gunn2, Clifton D Fuller2, Beth Beadle2, Steven J Frank2, William N William4, Merrill Kies4, Adel K El-Naggar5, Randal Weber3, David I Rosenthal2, Jack Phan6. 1. Department of Radiation Oncology, University of Cincinnati, Cincinnati, Ohio. 2. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jphan@mdanderson.org.
Abstract
PURPOSE: To review our 15-year institutional experience using intensity modulated radiation therapy (IMRT) to reirradiate patients with head and neck squamous cell carcinomas (HNSCC) and identify predictors of outcomes and toxicity. METHODS AND MATERIALS: We retrospectively reviewed the records of 227 patients who received head and neck reirradiation using IMRT from 1999 to 2014. Patients treated with noncurative intent were excluded. Radiation-related acute and late toxicities were recorded. Prognostic variables included performance status, disease site, disease-free interval, chemotherapy, and RT dose and volume. Correlative analyses were performed separately for surgery and nonsurgery patients. RESULTS: Two hundred six patients (91%) were retreated with curative intent, and 173 had HNSCC histology; 104 (50%) underwent salvage resection, and 135 (66%) received chemotherapy. Median follow-up after reirradiation was 24.7 months. Clinical outcomes were worse for HNSCC patients, with 5-year locoregional control, progression-free survival, and overall survival rates of 53%, 22%, and 32%, respectively, compared with 74%, 59%, and 79%, respectively, for non-HNSCC patients. On multivariate analysis, concurrent chemotherapy and retreatment site were associated with tumor control, whereas performance status was associated with survival. Favorable prognostic factors specific to surgery patients were neck retreatment and lack of extracapsular extension, whereas for nonsurgery patients, these were a nasopharynx subsite and complete response to induction chemotherapy. Actuarial rates of grade ≥3 toxicity were 32% at 2 years and 48% at 5 years, with dysphagia or odynophagia being most common. Increased grade ≥3 toxicity was associated with retreatment volume >50 cm(3) and concurrent chemotherapy. CONCLUSIONS: Reirradiation with IMRT either definitively or after salvage surgery can produce promising local control and survival in selected patients with head and neck cancers. Treatment-related toxicity remains significant. Prognostic factors are emerging to guide multidisciplinary treatment approaches and clinical trial design.
PURPOSE: To review our 15-year institutional experience using intensity modulated radiation therapy (IMRT) to reirradiate patients with head and neck squamous cell carcinomas (HNSCC) and identify predictors of outcomes and toxicity. METHODS AND MATERIALS: We retrospectively reviewed the records of 227 patients who received head and neck reirradiation using IMRT from 1999 to 2014. Patients treated with noncurative intent were excluded. Radiation-related acute and late toxicities were recorded. Prognostic variables included performance status, disease site, disease-free interval, chemotherapy, and RT dose and volume. Correlative analyses were performed separately for surgery and nonsurgery patients. RESULTS: Two hundred six patients (91%) were retreated with curative intent, and 173 had HNSCC histology; 104 (50%) underwent salvage resection, and 135 (66%) received chemotherapy. Median follow-up after reirradiation was 24.7 months. Clinical outcomes were worse for HNSCC patients, with 5-year locoregional control, progression-free survival, and overall survival rates of 53%, 22%, and 32%, respectively, compared with 74%, 59%, and 79%, respectively, for non-HNSCC patients. On multivariate analysis, concurrent chemotherapy and retreatment site were associated with tumor control, whereas performance status was associated with survival. Favorable prognostic factors specific to surgery patients were neck retreatment and lack of extracapsular extension, whereas for nonsurgery patients, these were a nasopharynx subsite and complete response to induction chemotherapy. Actuarial rates of grade ≥3 toxicity were 32% at 2 years and 48% at 5 years, with dysphagia or odynophagia being most common. Increased grade ≥3 toxicity was associated with retreatment volume >50 cm(3) and concurrent chemotherapy. CONCLUSIONS: Reirradiation with IMRT either definitively or after salvage surgery can produce promising local control and survival in selected patients with head and neck cancers. Treatment-related toxicity remains significant. Prognostic factors are emerging to guide multidisciplinary treatment approaches and clinical trial design.
Authors: Christina A Wicker; Brian G Hunt; Sunil Krishnan; Kathryn Aziz; Shobha Parajuli; Sarah Palackdharry; William R Elaban; Trisha M Wise-Draper; Gordon B Mills; Susan E Waltz; Vinita Takiar Journal: Cancer Lett Date: 2021-01-12 Impact factor: 8.679
Authors: Linton T Evans; Franco DeMonte; David R Grosshans; Amol J Ghia; Ahmed Habib; Shaan M Raza Journal: J Neurol Surg B Skull Base Date: 2019-02-21
Authors: Sulsal Haque; Vidhya Karivedu; Muhammed K Riaz; David Choi; Logan Roof; Sarah Z Hassan; Zheng Zhu; Roman Jandarov; Vinita Takiar; Alice Tang; Trisha Wise-Draper Journal: Oral Oncol Date: 2018-11-16 Impact factor: 5.337
Authors: Julie Schatteman; Dirk Van Gestel; Dieter Berwouts; Werner De Gersem; Geert De Kerf; Wilfried De Neve; Bie De Ost; Ana Maria Luiza Olteanu; Sylvie Rottey; Tom Vercauteren; Ingeborg Goethals; Fréderic Duprez Journal: Strahlenther Onkol Date: 2018-03-19 Impact factor: 3.621
Authors: Jimmy J Caudell; Matthew C Ward; Nadeem Riaz; Sara J Zakem; Musaddiq J Awan; Neal E Dunlap; Derek Isrow; Comron Hassanzadeh; John A Vargo; Dwight E Heron; Samuel Marcrom; Drexell H Boggs; Chandana A Reddy; Joshua Dault; James A Bonner; Kristin A Higgins; Jonathan J Beitler; Shlomo A Koyfman; Mitchell Machtay; Min Yao; Andy M Trotti; Farzan Siddiqui; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-01 Impact factor: 7.038
Authors: Alexander F Bagley; Adam S Garden; Jay P Reddy; Amy C Moreno; Steven J Frank; David I Rosenthal; William H Morrison; Gary Brandon Gunn; Clifton D Fuller; Shalin J Shah; Renata Ferrarotto; Erich M Sturgis; Neil D Gross; Jack Phan Journal: Head Neck Date: 2020-08-09 Impact factor: 3.147